Real world experience of efficacy and safety using Proprotein convertase subtilisin / Kexin 9 (PCSK9) inhibition in patients with familial hypercholesterolemia
19 May 2017 (08:30 - 18:00)
Organised by:
Abstract
About the speaker

Erasmus University Medical Centre, Rotterdam (Netherlands (The))
13 More presentations in this session
Access the full session
The Event
EuroHeartCare 2017
19 May 2017
08:30 CET
